DYADIC International Inc. announced that the expansion of its research laboratory in the Netherlands is now completed.
Dyadic, based in Jupiter, Fla., is a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries.
The expansion significantly increased floor space at Dyadic Netherlands, allowing for the installation of a wide range of state-of-the-art research equipment, including a new fermentation lab.
In addition, the expansion will facilitate the housing of new scientists who were recently hired for new projects involving the company's C1 expression technology. Dyadic increased its scientific staff by 40% in 2013 and plans to continue hiring molecular biologists, enzymologists and fermentation specialists through 2014.
Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large-scale manufacture of low-cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes.
Chief operating officer Danai Brooks said, "Commercial interest in Dyadic's C1 expression technology has increased with new end markets, such as biopharmaceuticals, and new customers. ... By investing in our (research and development) capabilities, we are able to expand our new product development pipeline, take on additional projects with our strategic partners and invest in strengthening the technology platform."
Wim van der Wilden, general manager of Dyadic Netherlands, added, "The expansion was necessary to meet the projected needs of the market. In the past year, we have seen a growing interest for our C1 system with commercial and academic parties. Having these state-of-the-art facilities, in combination with a larger scientific staff, will allow us to take on additional projects while broadening our services to the market."
A grand opening ceremony for the facility in Wageningen, Netherlands, will be held March 6.